Evidence map›Paper›PMID 27645234›Full record

ArticleAntimicrobial agents and chemotherapy2016

Evaluation of Propranolol Effect on Experimental Acute and Chronic Toxoplasmosis Using Quantitative PCR.

Mahbobeh Montazeri, Mohammad Ali Ebrahimzadeh, Ehsan Ahmadpour, Mehdi Sharif, Shahabeddin Sarvi, Ahmad Daryani

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Protective efficacy ofFrontiers in cellular and infection microbiology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Effect of Imiquimod on Tachyzoites ofFrontiers in cellular and infection microbiology · 2020
    Article
  13. Article
  14. Anti-Journal of pharmacopuncture · 2017
    Article
  15. A Systematic Review ofFrontiers in microbiology · 2017
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mahbobeh MontazeriToxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Mohammad Ali EbrahimzadehPharmaceutical Sciences Research Center, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Ehsan AhmadpourInfectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mehdi SharifToxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Shahabeddin SarviToxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Ahmad DaryaniToxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran daryanii@yahoo.com.
Mazandaran University of Medical Sciences · IRTabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current therapies against toxoplasmosis are limited, and drugs have significant side effects and low efficacies. We evaluated the potential anti-Toxoplasma activity of propranolol at a dose of 2 or 3 mg/kg of body weight/day in vivo in the acute and chronic phases. Propranolol as a cell membrane-stabilizing agent is a suitable drug for inhibiting the entrance of Toxoplasma gondii tachyzoites into cells. The acute-phase assay was performed using propranolol, pyrimethamine, and propranolol plus pyrimethamine before (pretreatment) and after (posttreatment) intraperitoneal challenge with 1 × 10

Indexed as

AnimalsAntiprotozoal AgentsChronic DiseaseDose-Response Relationship, DrugFemaleMice, Inbred BALB CParasite LoadPropranololReal-Time Polymerase Chain ReactionSurvival RateToxoplasmaToxoplasmosis, AnimalAntiprotozoal AgentsPropranolol

Identifiers

PMID27645234
PMCPMC5118991
OpenAlexW2552098157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.